Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 298 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo inhaler Clear all

Conditions: Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Interventions: treprostinil SMI (treprostinil inhalation spray), Placebo (placebo inhalation spray); Combination Product
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 12 more

Conditions: Asthma
Interventions: BI 671800, Fluticasone propionate placebo, Fluticasone propionate, BI 671800 Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 40
States / cities: Tucson, Arizona • Cypress, California • Los Angeles, California + 34 more

Conditions: Asthma
Interventions: Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg, Albuterol sulfate metered dose inhaler / AS MDI 180 μg, Placebo metered-dose inhaler / Placebo MDI; Combination Product · Drug · Other
Lead sponsor: Bond Avillion 2 Development LP; Industry
Eligibility: 4 Years and older
Enrollment: 1,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 73
States / cities: Mobile, Alabama • Bakersfield, California • Costa Mesa, California + 60 more

Conditions: Asthma
Interventions: Fp MDPI, Flovent Diskus, albuterol/salbutamol, Placebo MDPI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 129
States / cities: Homewood, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 104 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more

Conditions: Asthma
Interventions: Fluticasone propionate/Formoterol fumarate 250/10, Placebo, Fluticasone propionate/Formoterol fumarate 100/10, Fluticasone propionate 250, Formoterol fumarate 10; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 62
States / cities: Pell City, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more

Conditions: COVID-19
Interventions: Ciclesonide, Placebo; Drug
Lead sponsor: Covis Pharma S.à.r.l.; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Asthma
Interventions: Bronchodilator; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 9
States / cities: San Diego, California • Savannah, Georgia • Louisville, Kentucky + 6 more

Conditions: Eosinophilic Esophagitis
Interventions: Oral Viscous Budesonide, Fluticasone MDI, Placebo slurry, Placebo inhaler; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 80 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Emphysema, Poor Sleep Quality
Interventions: Budesonide/formoterol, Placebo; Drug
Lead sponsor: Temple University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI 62.5/25 mcg via ELLIPTA, UMEC 62.5 mcg via ELLIPTA, Salmeterol 50 mcg via DISKUS, Placebo via ELLIPTA, Placebo via DISKUS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 2,696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 37
States / cities: Phoenix, Arizona • Lincoln, California • Clearwater, Florida + 34 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo, tiotropium + Olodaterol, Tiotropium, Olodaterol, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more

Conditions: Asthma
Interventions: Fluticasone propionate pressurized metered dose inhaler, Flovent HFA pressurized metered dose inhaler, Placebo pressurized metered dose inhaler; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Asthma
Interventions: Epinephrine HFA-MDI (E004), Placebo-HFA; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Cypress, California • Medford, Oregon • Portland, Oregon + 3 more

Conditions: Asthma
Interventions: Fluticasone furoate 50mcg, Fluticasone propionate 100mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Los Angeles, California • Rolling Hills Estates, California • Sacramento, California + 17 more

Conditions: Arterial Stiffness
Interventions: E-cigarette, Nicotine 0%, Menthol Inhalant Product; Drug
Lead sponsor: University of Texas at Austin; Other
Eligibility: 20 Years to 30 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Asthma
Interventions: QAW039, Placebo QAW039, Fluticasone 250 mcg, Fluticasone 100 mcg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 30
States / cities: Encinitas, California • Huntington Beach, California • Los Angeles, California + 24 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BEA 2180 BR, tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 83 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 27
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 23 more

Conditions: Type 2 Diabetes
Interventions: Technosphere® Insulin, Technosphere Powder; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 50
States / cities: Anaheim, California • Huntington Beach, California • Laguna Hills, California + 41 more

Conditions: COPD
Interventions: Indacaterol, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 93
States / cities: Homewood, Alabama • Jasper, Alabama • Phoenix, Arizona + 83 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium + olodaterol, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 21
States / cities: Andalusia, Alabama • Jasper, Alabama • Brandon, Florida + 18 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 40 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 76
States / cities: Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 16
States / cities: Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more

Conditions: Asthma
Interventions: Placebo DPI, ELLIPTA DPI, Ease of use questionnaires; Drug · Device · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 15
States / cities: Little Rock, Arkansas • Huntington Beach, California • Napa, California + 12 more

Search by objective public record fields.

Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

BI 671800 ED in Steroid-naive Asthmatic Patients

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients

Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics

Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis

Effect of Symbicort on Sleep Quality in Patients With Emphysema

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg

Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

Vascular Effects of a Single Bout of Electronic Cigarette Use

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

Dose Finding Study in COPD

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma